The investment will be made in the form of SAFE (Simple Agreement for Future Equity) Notes, which will convert into a percentage of shareholding upon fulfilment of certain conditions.
“Shilpa Medicare has always been at the forefront of enabling breakthrough biologics with our world‐class development and manufacturing capabilities,” said Vishnukant Bhutada, Managing Director, Shilpa Medicare Limited. “This partnership with Alveolus Bio not only strengthens our innovation pipeline but also positions Shilpa as a key global partner for biotech companies looking to translate bold science into scalable clinical and commercial solutions.”
The investment will fund Alveolus Bio’s lead COPD program through Phase 2 clinical trials and accelerate additional preclinical programs. Importantly, the collaboration also creates a platform for co‐development and future manufacturing partnerships.
“This partnership with Shilpa Medicare is not just about funding—it’s about combining deep biotech innovation with proven pharmaceutical execution,” said Gaurav Mehta, CEO of Alveolus Bio. “Together, we can deliver these life‐changing therapies to patients much faster and more efficiently.”
The move aligns with Shilpa’s strategy to expand its biologics footprint, diversify into innovative therapeutic platforms, and build strategic alliances with disruptive biotech companies globally, according to the release.
“The science at Alveolus Bio represents a paradigm shift in respiratory medicine,” added Dr. C. Vivek Lal, Founder and Chief Scientific Officer of Alveolus Bio. “This partnership seamlessly bridges cutting‐ edge biotech innovation with Shilpa’s global pharmaceutical leadership, enabling rapid clinical translation of our novel therapies.”
Alveolus Bio, a company based out of USA is pioneering breakthrough therapeutic assets for lung diseases through its proprietary resMIT platform. The company's pipeline includes preclinical phase live biotherapeutics for Chronic Obstructive Pulmonary Disease (COPD), Bronchopulmonary Dysplasia (BPD), Pulmonary Fibrosis, Lung Injury Secondary to Viral Infection, Neutrophilic Asthma, and earlier‐stage programs including Cystic Fibrosis (CF), Pulmonary Arterial Hypertension (PAH), and Acute Respiratory Distress Syndrome. Alveolus Bio has offices in Birmingham, AL and Cambridge, MA
The SAFE notes investment is expected to be completed within a month of signing the definitive agreements.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.